Products

5-(2-fluorophenyl)-1H-pyrrole-3-carcoalonitrile is an organic compound. 

Vonorazan (CAS number: 881681-00-1), chemical name 1-[5-(2-fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl]-N-methylmethanamine, is a new type of anti-gastric acid drug, which belongs to potassium competitive acid blocker (P-CAB). Developed by Takeda Pharmaceutical in collaboration with Otsuka Pharmaceutical, Wonolazan is used to treat gastric acid-related diseases such as erosive esophagitis, gastric ulcers, and duodenal ulcers.

5-(2-fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrole-3-carboxaldehyde is an intermediate in the synthesis of vonorazan fumarate. Vornorazan fumarate is a novel potassium ion (K+) competitive acid blocker (ChemicalbookP-CAB), which can prematurely terminate the secretion of gastric acid by inhibiting the binding effect of K+ to H+―K+-ATPase (proton pump) in the last ring of gastric acid secretion in gastric parietal cells, and has a powerful and long-lasting inhibitory effect on gastric acid secretion.
5-(2-fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrole-3-carboxaldehyde, often abbreviated as FPyS, is an organic compound.

5-(2-fluorophenyl)-1H-pyrrole-3-carboxaldehyde is an organic compound.

Pyridine-3-sulfonyl chloride is an organic compound.